Stay updated on Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.

Latest updates to the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the expected study content and indicating the page is currently inaccessible.SummaryDifference20%

- Check16 days agoNo Change Detected
- Check30 days agoChange DetectedThe NIH funding note 2016 ( U.S. NIH Grant/Contract ) was added to the study metadata, and the page revision was updated to v3.6.6 (replacing v3.6.5).SummaryDifference0.1%

- Check44 days agoChange DetectedThe page now displays the full study record for NCT03222856, replacing the prior error page and including the study overview, eligibility criteria, and locations.SummaryDifference64%

- Check51 days agoChange DetectedThe page now displays Revision: v3.6.5 instead of Revision: v3.6.4, reflecting a small version update.SummaryDifference0.0%

- Check65 days agoChange DetectedRevision: v3.6.4 is now displayed, replacing Revision: v3.6.3. This update seems to be a site version update rather than a substantive change to the study information.SummaryDifference0.0%

- Check87 days agoChange DetectedRevision: v3.6.3 is now displayed, replacing Revision: v3.6.2. This indicates a version update for the page/system rather than a content addition or removal.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.